OTTAWA, Feb. 16, 2012 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce the appointment of Deborah M. Brown, President and Managing Director, EMD Inc., Canada as Chair of the Board of Directors for 2012. Ms. Brown assumes the role as Chair in light of the departure of Mr. Philip Blake, former President and CEO at Bayer who was recently promoted to Head of Region USA of Bayer HealthCare Pharmaceuticals.
Ms. Brown was first elected to the Rx&D Board of Directors in 2007.
Ms. Brown is the President and Managing Director of EMD Inc., Canada, an affiliate of Merck KGaA, headquartered in Darmstadt, Germany. She completed undergraduate and graduate studies in science and business from the Universities of Guelph and the Richard Ivey School of Business at University of Western Ontario. Her pharmaceutical career has included positions in regulatory affairs, biometrics, sales management, research, marketing, and general management. In her current role, she oversees one of Canada's most successful commercial biotechnology companies, offering or developing niche prescription medicines.
Ms. Brown is involved in her community and several charitable organizations - a founding member of Women Against MS (WAMS), which is a special fundraising group of the MS Society and the two organizations that EMD actively supports - Halton Women's Place and Future Possibilities for Kids.
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
For further information:
E-mail: [email protected]